Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid

被引:45
作者
Goosen, Theunis C.
Bauman, Jonathan N.
Davis, John A.
Yu, Chongwoo
Hurst, Susan I.
Williams, J. Andrew
Loi, Cho-Ming
机构
[1] Dept Pharmakokinetics Dynam & Metab, Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA
[2] Amgen Inc, Seattle, WA USA
关键词
D O I
10.1124/dmd.107.015230
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gemfibrozil coadministration generally results in plasma statin area under the curve (AUC) increases, ranging from moderate (2-to 3-fold) with simvastatin, lovastatin, and pravastatin to most significant with cerivastatin (5.6-fold). Inhibition of statin glucuronidation has been postulated as a potential mechanism of interaction (Drug Metab Dispos 30:1280-1287, 2002). This study was conducted to determine the in vitro inhibitory potential of fibrates toward atorvastatin glucuronidation. [H-3] Atorvastatin, atorvastatin, and atorvastatin lactone were incubated with human liver microsomes or human recombinant UDP-glucuronosyltransferases (UGTs) and characterized using liquid chromatography (LC)/tandem mass spectrometry and LC/UV/beta-radioactivity monitor/mass spectrometry. [ 3H] Atorvastatin yields a minor ether glucuronide (G1) and a major acyl glucuronide (G2) with subsequent pH-dependent lactonization of G2 to yield atorvastatin lactone. Atorvastatin lactonization best fit substrate inhibition kinetics (K-m = 12 mu M, V-max = 74 pmol/min/mg, K-i = 75 mu M). Atorvastatin lactone yields a single ether glucuronide (G3). G3 formation best fit Michaelis-Menten kinetics (K-m = 2.6 mu M, V-max = 10.6 pmol/min/mg). Six UGT enzymes contribute to atorvastatin glucuronidation with G2 and G3 formation catalyzed by UGTs 1A1, 1A3, 1A4, 1A8, and 2B7, whereas G1 formation was catalyzed by UGTs 1A3, 1A4, and 1A9. Gemfibrozil, fenofibrate, and fenofibric acid inhibited atorvastatin lactonization with IC50 values of 346, 320, and 291 mu M, respectively. Based on unbound fibrate concentrations at the inlet to the liver, these data predict a small increase in atorvastatin AUC (similar to 1.2-fold) after gemfibrozil coadministration and no interaction with fenofibrate. This result is consistent with recent clinical reports indicating minimal atorvastatin AUC increases (similar to 1.2-to 1.4-fold) with gemfibrozil.
引用
收藏
页码:1315 / 1324
页数:10
相关论文
共 40 条
[1]   Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites [J].
Backman, JT ;
Lulurila, H ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) :154-167
[2]   Gemfibrozil greatly increases plasma concentrations of cerivastatin [J].
Backman, JT ;
Kyrklund, C ;
Neuvonen, M ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) :685-691
[3]   Plasma concentrations of active simvastatin acid are increased by gemfibrozil [J].
Backman, JT ;
Kyrklund, C ;
Kivistö, KT ;
Wang, JS ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :122-129
[4]   Statin safety: An overview and assessment of the data-2005 [J].
Bays, H .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :6C-26C
[5]   Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans [J].
Bergman, AJ ;
Murphy, G ;
Burke, J ;
Zhao, JJ ;
Valesky, R ;
Liu, L ;
Lasseter, KC ;
He, WL ;
Prueksaritanont, T ;
Qiu, Y ;
Hartford, A ;
Vega, JM ;
Paolini, JE .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (09) :1054-1062
[6]   Statin safety and drug interactions: Clinical implications [J].
Bottorff, MB .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :27C-31C
[7]   Prediction of in vivo drug-drug interactions from in vitro data:: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant [J].
Brown, HS ;
Ito, K ;
Galetin, A ;
Houston, JB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (05) :508-518
[8]   Differential interaction of 3-hydroxy-3-methylglutaryl-COA reductase inhibitors with ABCB1, ABCC2, and OATP1B1 [J].
Chen, CP ;
Mireles, RJ ;
Campbell, SD ;
Lin, J ;
Mills, JB ;
Xu, JHJ ;
Smolarek, TA .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (04) :537-546
[9]   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].
Grundy, SM ;
Cleeman, JI ;
Merz, CNB ;
Brewer, HB ;
Clark, LT ;
Hunninghake, DB ;
Pasternak, RC ;
Smith, SC ;
Stone, NJ .
CIRCULATION, 2004, 110 (02) :227-239
[10]   Benefit versus risk in statin treatment [J].
Guyton, JR .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :95C-97C